Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    13

Stocks News & Analysis

stocks

Market too pessimistic about unloved ASX health care share

Our analysts believe a long-term margin recovery is underway.
stocks

Two overvalued ASX shares to avoid

Both shares trade at a significant premium to our fair value.
stocks

Materially undervalued ASX tech share

Long reinvestment runway supports our thesis on ASX technology company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,899.306.50-0.07%
CAC 408,052.0226.220.33%
DAX 4023,508.8744.240.19%
Dow JONES (US)47,112.45664.181.43%
FTSE 1009,629.5620.030.21%
HKSE25,928.0833.530.13%
NASDAQ23,025.59153.590.67%
Nikkei 22549,559.07899.551.85%
NZX 50 Index13,562.0181.580.61%
S&P 5006,765.8860.760.91%
S&P/ASX 2008,606.509.50-0.11%
SSE Composite Index3,864.185.84-0.15%

Market Movers